JP2024534503A - 形質転換されていないマクロファージ細胞株の生成方法 - Google Patents

形質転換されていないマクロファージ細胞株の生成方法 Download PDF

Info

Publication number
JP2024534503A
JP2024534503A JP2024517432A JP2024517432A JP2024534503A JP 2024534503 A JP2024534503 A JP 2024534503A JP 2024517432 A JP2024517432 A JP 2024517432A JP 2024517432 A JP2024517432 A JP 2024517432A JP 2024534503 A JP2024534503 A JP 2024534503A
Authority
JP
Japan
Prior art keywords
macrophages
porcine
cells
transformed
macrophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534503A5 (https=
Inventor
フェジェル、ジョルジ
ロパテッカ、ユスティナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plymouth University
Original Assignee
Plymouth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2113747.6A external-priority patent/GB202113747D0/en
Priority claimed from GBGB2210102.6A external-priority patent/GB202210102D0/en
Application filed by Plymouth University filed Critical Plymouth University
Publication of JP2024534503A publication Critical patent/JP2024534503A/ja
Publication of JP2024534503A5 publication Critical patent/JP2024534503A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2024517432A 2021-09-27 2022-09-22 形質転換されていないマクロファージ細胞株の生成方法 Pending JP2024534503A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2113747.6A GB202113747D0 (en) 2021-09-27 2021-09-27 Method for the generation of non-transformed macrophage cell line
GB2113747.6 2021-09-27
GBGB2210102.6A GB202210102D0 (en) 2022-07-09 2022-07-09 Method for generation of non-transformed macrophage cell line
GB2210102.6 2022-07-09
PCT/EP2022/076456 WO2023046873A1 (en) 2021-09-27 2022-09-22 Method for the generation of non-transformed macrophage cell line

Publications (2)

Publication Number Publication Date
JP2024534503A true JP2024534503A (ja) 2024-09-20
JP2024534503A5 JP2024534503A5 (https=) 2025-10-01

Family

ID=83995013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517432A Pending JP2024534503A (ja) 2021-09-27 2022-09-22 形質転換されていないマクロファージ細胞株の生成方法

Country Status (9)

Country Link
EP (1) EP4408983A1 (https=)
JP (1) JP2024534503A (https=)
KR (1) KR20240067919A (https=)
AR (1) AR127140A1 (https=)
AU (1) AU2022351386A1 (https=)
CA (1) CA3233040A1 (https=)
MX (1) MX2024003500A (https=)
UY (1) UY39959A (https=)
WO (1) WO2023046873A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012933A1 (en) * 2012-07-16 2014-01-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of non-transformed macrophage cell lines

Also Published As

Publication number Publication date
KR20240067919A (ko) 2024-05-17
EP4408983A1 (en) 2024-08-07
MX2024003500A (es) 2024-04-04
WO2023046873A1 (en) 2023-03-30
CA3233040A1 (en) 2023-03-30
UY39959A (es) 2023-04-14
AR127140A1 (es) 2023-12-20
AU2022351386A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US8133732B2 (en) Method of forming myeloid precursor cells from human embryonic stem cells
JP6013187B2 (ja) ヒト胚性幹細胞由来血管芽細胞からナチュラルキラー細胞および樹状細胞を生成する方法
Schäfer et al. Porcine invariant natural killer T cells: functional profiling and dynamics in steady state and viral infections
US20050191743A1 (en) Three-dimensional peripheral lymphoid organ cell cultures
Pigni et al. Establishment and characterization of a functionally competent type 2 conventional dendritic cell line
Grau-Vorster et al. Characterization of a cytomegalovirus-specific T lymphocyte product obtained through a rapid and scalable production process for use in adoptive immunotherapy
Ramadan et al. Generation of Aspergillus-and CMV-specific T-cell responses using autologous fast DC
CN108220243B (zh) 一种多能干细胞及其分化的t细胞和应用
CN104491857B (zh) 一种用于免疫治疗ebv相关疾病的抗原组合物、生物制剂及其制备方法
CN105441390A (zh) Nk细胞的体外三维扩增培养方法
JP2024534503A (ja) 形質転換されていないマクロファージ細胞株の生成方法
US20240392246A1 (en) Method for the Generation of Non-Transformed Macrophage Cell Line
Münz Immune Control and vaccination against the Epstein–Barr virus in humanized mice
CN118019841A (zh) 用于产生非转化巨噬细胞系的方法
Smerchansky et al. Engineered multicellular niches for pluripotent stem cell–derived immunotherapy
TWI891439B (zh) 低免疫原性多能幹細胞誘導分化成免疫細胞的方法
Kang Targeting Pyruvate Metabolism Leads to Distinct CD8+ T Cell Responses to Virus Infection and Cancer
US3418210A (en) Hamster ascites tumor cell line bhk 21/c.13/t.6/ascites useful in submerged serum-free agar cultures to support virus growth
Prockop et al. Viral Cytotoxic T Lymphocytes (CTLs): From Bench to Bedside
KR101552610B1 (ko) 육아종 동물모델 및 그 제조방법
US20050003526A1 (en) Pig mast cell cultures and uses thereof
Mair et al. Porcine plasmacytoid dendritic cells are unique in their expression of a functional NKp46 receptor
Finberg Epstein–Barr virus–specific T cells for the management of Epstein–Barr virus lymphomas
JP2020503335A (ja) Ｔ細胞を得る方法及び使用
JP2024518632A (ja) 体液免疫系の再生方法およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250922